Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CALT vs. TVTX, ICPT, OMER, ENTA, NGM, BHVN, CRNX, BBIO, RARE, and IMVTShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Travere Therapeutics (TVTX), Intercept Pharmaceuticals (ICPT), Omeros (OMER), Enanta Pharmaceuticals (ENTA), NGM Biopharmaceuticals (NGM), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), and Immunovant (IMVT). These companies are all part of the "medical" sector. Calliditas Therapeutics AB (publ) vs. Travere Therapeutics Intercept Pharmaceuticals Omeros Enanta Pharmaceuticals NGM Biopharmaceuticals Biohaven Crinetics Pharmaceuticals BridgeBio Pharma Ultragenyx Pharmaceutical Immunovant Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking. Which has more risk & volatility, CALT or TVTX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Does the media prefer CALT or TVTX? In the previous week, Travere Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 7 mentions for Travere Therapeutics and 1 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.90 beat Travere Therapeutics' score of 0.74 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calliditas Therapeutics AB (publ) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, CALT or TVTX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Travere Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Travere Therapeutics$145.24M9.52-$111.40M-$4.55-3.89 Is CALT or TVTX more profitable? Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Travere Therapeutics' net margin of -172.75%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Travere Therapeutics -172.75%-537.74%-55.65% Do analysts rate CALT or TVTX? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Travere Therapeutics has a consensus price target of $22.62, suggesting a potential upside of 27.63%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Do insiders and institutionals hold more shares of CALT or TVTX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 3.8% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in CALT or TVTX? Travere Therapeutics received 50 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 57.04% of users gave Travere Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Travere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% SummaryCalliditas Therapeutics AB (publ) and Travere Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-21.624.8266.7313.27Price / Sales0.74374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book37.749.636.455.92Net Income-$43.96M$154.43M$119.73M$225.73M7 Day PerformanceN/A-9.46%-5.13%-1.34%1 Month PerformanceN/A-7.27%-2.71%1.15%1 Year Performance131.35%28.13%31.08%24.02% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180News CoverageTVTXTravere Therapeutics3.1218 of 5 stars$18.78-1.3%N/A+194.8%$1.47B$203.45M-4.13460Analyst ForecastICPTIntercept Pharmaceuticals0.6743 of 5 stars$19.00flatN/AN/A$794.77M$285.71M-12.84341Analyst ForecastOMEROmeros3.7333 of 5 stars$4.26-0.7%N/A+347.0%$246.85MN/A-1.81198Analyst DowngradeNews CoverageENTAEnanta Pharmaceuticals3.9626 of 5 stars$10.60-2.5%N/A+9.7%$224.61M$79.20M-1.94145Upcoming EarningsNGMNGM Biopharmaceuticals3.5585 of 5 stars$1.54-1.3%N/A+155.2%$128.53M$4.42M-0.90138BHVNBiohaven3.811 of 5 stars$50.25-4.2%N/A+49.6%$4.75B$462.51M-5.49239Earnings ReportAnalyst ForecastNews CoverageCRNXCrinetics Pharmaceuticals3.5501 of 5 stars$58.75-2.1%N/A+93.1%$4.70B$4.01M-15.54210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageBBIOBridgeBio Pharma4.6019 of 5 stars$24.45-6.4%N/A-17.8%$4.60B$9.30M-9.30400Analyst ForecastAnalyst RevisionNews CoverageRAREUltragenyx Pharmaceutical4.6264 of 5 stars$48.06-5.3%N/A+14.9%$4.44B$434.25M-7.431,276Analyst ForecastIMVTImmunovant1.6351 of 5 stars$28.99-6.9%N/A-21.0%$4.24BN/A-13.06120Positive News Related Companies and Tools Related Companies Travere Therapeutics Alternatives Intercept Pharmaceuticals Alternatives Omeros Alternatives Enanta Pharmaceuticals Alternatives NGM Biopharmaceuticals Alternatives Biohaven Alternatives Crinetics Pharmaceuticals Alternatives BridgeBio Pharma Alternatives Ultragenyx Pharmaceutical Alternatives Immunovant Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
